{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:27:58Z","timestamp":1787390878030,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tigecycline is frequently used to treat multidrug-resistant infections in critically ill patients. However, its pharmacokinetics in patients receiving extracorporeal membrane oxygenation (ECMO) are poorly defined, raising concerns about the adequacy of standard dosing in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This prospective, multicentre pilot study included adult ICU patients receiving venovenous (VV) or venoarterial (VA) ECMO and standard tigecycline dosing. Serial plasma samples were collected at steady state to determine tigecycline concentrations using liquid chromatography\u2013tandem mass spectrometry. Pharmacokinetic parameters, including maximum plasma concentration (C\n                      <jats:sub>max<\/jats:sub>\n                      ), trough plasma concentration (C\n                      <jats:sub>min<\/jats:sub>\n                      ), area under the concentration\u2013time curve (AUC), and systemic clearance (CL), were calculated. Microbiological samples were obtained before therapy initiation. Pharmacokinetic parameters were compared between ECMO configurations and correlations with organ function markers were assessed using Spearman analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifteen patients were included (13 VV-ECMO, 2 VA-ECMO). Marked interindividual variability in tigecycline exposure was observed. Median C\n                      <jats:sub>max<\/jats:sub>\n                      was 0.50\u00a0\u00b5g\/mL, with consistently low trough concentrations. Plasma levels generally exceeded EUCAST MIC breakpoints for Gram-positive pathogens but were lower for Gram-negative organisms. Patients receiving VA-ECMO exhibited numerically higher tigecycline exposure than those on VV-ECMO. Moderate, non-significant positive correlations were observed between total bilirubin levels and tigecycline exposure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tigecycline pharmacokinetics in ECMO-supported critically ill patients show high variability, with higher exposure in VA-ECMO than in VV-ECMO. Standard dosing may be insufficient, supporting therapeutic drug monitoring and further studies to inform individualized dosing strategies in this complex population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12871-026-04114-1","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T01:35:46Z","timestamp":1785980146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tigecycline pharmacokinetics in critically ill patients receiving extracorporeal membrane oxygenation: a prospective multicentre pilot study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4678-3576","authenticated-orcid":false,"given":"Rawan","family":"Alraish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2456-8736","authenticated-orcid":false,"given":"Afrah","family":"Alkazemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2854-980X","authenticated-orcid":false,"given":"Kamal M.","family":"Matar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara F.","family":"Buabbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Al-Mutawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9475-7976","authenticated-orcid":false,"given":"Abdulrahman","family":"Al-fares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"4114_CR1","unstructured":"Extracorporeal Life Support Organization (ELSO). ELSO Registry Report. Available from: https:\/\/www.elso.org. (Accessed Jul 2025)."},{"issue":"5","key":"4114_CR2","doi-asserted-by":"publisher","first-page":"R194","DOI":"10.1186\/cc11679","volume":"16","author":"K Shekar","year":"2012","unstructured":"Shekar K, Roberts JA, McDonald CI, et al. Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care. 2012;16(5):R194.","journal-title":"Crit Care"},{"issue":"2","key":"4114_CR3","first-page":"291","volume":"29","author":"KM Watt","year":"2013","unstructured":"Watt KM, Benjamin DK, Cheifetz IM. Pediatric extracorporeal membrane oxygenation: current management strategies and future challenges. Crit Care Clin. 2013;29(2):291\u2013303.","journal-title":"Crit Care Clin"},{"issue":"12","key":"4114_CR4","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00134-010-2041-z","volume":"36","author":"ED Wildschut","year":"2010","unstructured":"Wildschut ED, Ahsman MJ, Allegaert K, Mathot RA, Tibboel D. Determinants of drug absorption in different ECMO circuits. Intensive Care Med. 2010;36(12):2109\u201316.","journal-title":"Intensive Care Med"},{"issue":"2","key":"4114_CR5","first-page":"276","volume":"46","author":"V Cheng","year":"2020","unstructured":"Cheng V, Abdul-Aziz MH, Roberts JA. Optimising antimicrobial therapy in critically ill patients receiving extracorporeal membrane oxygenation. Intensive Care Med. 2020;46(2):276\u201388.","journal-title":"Intens Care Med"},{"key":"4114_CR6","unstructured":"European Medicines Agency. Tigecycline summary of product characteristics. Available from: https:\/\/www.ema.europa.eu.\u00a0 (Accessed July 2025)."},{"issue":"4","key":"4114_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.diagmicrobio.2012.12.004","volume":"75","author":"GE Stein","year":"2013","unstructured":"Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis. 2013;75(4):331\u20136.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"4114_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/jac\/29.3.245","volume":"29","author":"I Chopra","year":"1992","unstructured":"Chopra I, Hawkey P, Hinton M. Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother. 1992;29(3):245\u201377.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 5","key":"4114_CR9","first-page":"S333","volume":"41","author":"GE Stein","year":"2005","unstructured":"Stein GE, Schooley SL, Marsh PC, et al. Pharmacokinetics and pharmacodynamics of tigecycline. Clin Infect Dis. 2005;41(Suppl 5):S333\u201340.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4114_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.diagmicrobio.2005.05.006","volume":"52","author":"AK Meagher","year":"2005","unstructured":"Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic\/pharmacodynamic profile for tigecycline\u2014a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis. 2005;52(3):165\u201371.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"4114_CR11","unstructured":"U.S. Food and Drug Administration. Tigecycline (Tygacil) Prescribing Information. Available from: https:\/\/www.accessdata.fda.gov. (Accessed July 2025)."},{"key":"4114_CR12","doi-asserted-by":"publisher","first-page":"1083464","DOI":"10.3389\/fphar.2023.1083464","volume":"14","author":"C Luo","year":"2023","unstructured":"Luo C, Li L, Zhang Y, et al. Population pharmacokinetics of tigecycline in critically ill patients: implications for dose optimization. Front Pharmacol. 2023;14:1083464.","journal-title":"Front Pharmacol"},{"issue":"9","key":"4114_CR13","first-page":"2595","volume":"75","author":"C K\u00f6nig","year":"2020","unstructured":"K\u00f6nig C, R\u00f6hr AC, Frey OR, et al. Pharmacokinetics of tigecycline in critically ill patients with liver impairment. J Antimicrob Chemother. 2020;75(9):2595\u2013602.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"4114_CR14","first-page":"1166","volume":"67","author":"A Veinstein","year":"2012","unstructured":"Veinstein A, Brossier D, Kac G, et al. Lack of effect of ECMO on tigecycline pharmacokinetics: a case report. J Antimicrob Chemother. 2012;67(5):1166\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"4114_CR15","first-page":"673404","volume":"12","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Chen Y, Fan H, et al. Sequestration of antibiotics in ECMO circuits: an ex vivo study. Front Pharmacol. 2021;12:673404.","journal-title":"Front Pharmacol"},{"issue":"4","key":"4114_CR16","first-page":"353","volume":"18","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Lipman J, Roberts JA. Antibiotic dosing in critically ill patients receiving extracorporeal membrane oxygenation. Expert Rev Anti Infect Ther. 2020;18(4):353\u201365.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"4114_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13613-020-00707-2","volume":"10","author":"R Alraish","year":"2020","unstructured":"Alraish R, Wicha SG, Frey OR, Roehr AC, Pratschke J, Stockmann M, et al. Pharmacokinetics of tigecycline in critically ill patients with liver failure defined by maximal liver function capacity test (LiMAx). Ann Intensive Care. 2020;10(1):106.","journal-title":"Ann Intensive Care"},{"issue":"1","key":"4114_CR18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13613-020-00715-2","volume":"10","author":"G De Pascale","year":"2020","unstructured":"De Pascale G, Lisi L, Ciotti GMP, Vallecoccia MS, Cutuli SL, Cascarano L, et al Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections. Ann Intensive Care. 2020;10(1):94. https:\/\/doi.org\/10.1186\/s13613-020-00715-2.","journal-title":"Ann Intensive Care"},{"key":"4114_CR19","doi-asserted-by":"publisher","unstructured":"Yao F, Wang Y, Hou Y, et al. Establishment and validation of a liquid chromatography-tandem mass spectrometry method for the determination of tigecycline in critically ill patients. Int J Anal Chem. 2020;6671392. https:\/\/doi.org\/10.1155\/2020\/6671392.","DOI":"10.1155\/2020\/6671392"},{"key":"4114_CR20","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 15.0. V\u00e4xj\u00f6: EUCAST; 2025. Available from: EUCAST Document Archive (Version 15.0)."},{"issue":"8","key":"4114_CR21","first-page":"1640","volume":"42","author":"KM Watt Jr","year":"2014","unstructured":"Watt KM, Benjamin DK Jr, Cheifetz IM. Pharmacokinetics of beta-lactams during ECMO. Crit Care Med. 2014;42(8):1640\u201359.","journal-title":"Crit Care Med"},{"issue":"3","key":"4114_CR22","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","volume":"37","author":"JA Roberts","year":"2009","unstructured":"Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840\u201351.","journal-title":"Crit Care Med"},{"issue":"4","key":"4114_CR23","first-page":"323","volume":"44","author":"SI Blot","year":"2014","unstructured":"Blot SI, Pea F, Lipman J. The influence of acute kidney injury on antimicrobial dosing in critically ill patients: a structured review. Int J Antimicrob Agents. 2014;44(4):323\u201330.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"4114_CR24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Davis JS, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498\u2013509.","journal-title":"Lancet Infect Dis"}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12871-026-04114-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-026-04114-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-026-04114-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:17:11Z","timestamp":1787390231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12871-026-04114-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4114"],"URL":"https:\/\/doi.org\/10.1186\/s12871-026-04114-1","relation":{},"ISSN":["1471-2253"],"issn-type":[{"value":"1471-2253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"1 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ministry of Health Standing Committee for Coordination of Health and Medical Research (Approval No. 2022\/1994). Written informed consent was obtained from patients or their legally authorized representatives prior to study participation. All procedures were performed in accordance with the ethical standards of the institutional and national research committees and with the Declaration of Helsinki and its subsequent amendments.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"519"}}